Literature DB >> 30732970

Gonococcal infection: An unresolved problem.

Maria Jesús Barberá1, Judit Serra-Pladevall2.   

Abstract

Gonococcal infection is a current public health problem worldwide, being the second most prevalent bacterial sexually transmitted infection. The etiologic agent is Neisseria gonorrhoeae, a gram-negative diplococcus, and mainly causes urethritis in men. In women up to 50% of infections can be asymptomatic. N. gonorrhoeae has a great ability to develop antibiotic resistance, so the last remaining therapeutic option are extended spectrum cephalosporins. Many guides recommend dual therapy with ceftriaxone and azithromycin, but in recent years the resistance to azithromycin is also increasing, so that dual treatment is being questioned by scientific societies.
Copyright © 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Diagnosis; Diagnóstico; Gonococcal infection; Infección gonocócica; Tratamiento; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30732970     DOI: 10.1016/j.eimc.2018.12.008

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin (Engl Ed)        ISSN: 2529-993X


  3 in total

1.  The Epidemiology and Outcomes of Septic Arthritis in the Maltese Islands: A Hospital-Based Retrospective Cohort Study.

Authors:  Christian Vassallo; Andrew A Borg; Daniel Farrugia; Cecilia Mercieca
Journal:  Mediterr J Rheumatol       Date:  2020-06-30

2.  Brazilian Protocol for Sexually Transmitted Infections, 2020: infections that cause urethral discharge.

Authors:  Leonor Henriette de Lannoy; Roberto José de Carvalho da Silva; Edilbert Pellegrini Nahn Júnior; Eduardo Campos de Oliveira; Pâmela Cristina Gaspar
Journal:  Rev Soc Bras Med Trop       Date:  2021-05-17       Impact factor: 1.581

3.  [Bacterial arthritis' clinical suspicion in an HIV patient].

Authors:  I Olaya García Rodríguez; L Sante Fernández; A Madueño Alonso; M M Alonso Socas; M Lecuona Fernández
Journal:  Rev Esp Quimioter       Date:  2021-03-16       Impact factor: 1.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.